<DOC>
	<DOCNO>NCT00827671</DOCNO>
	<brief_summary>The purpose study determine whether addition combination cetuximab radiotherapy standard chemotherapy resectable oesophageal cancer safe add efficacy .</brief_summary>
	<brief_title>Study Combination Cetuximab Radiotherapy Added Standard Treatment Oesophageal Adenocarcinoma</brief_title>
	<detailed_description>This study aim develop novel strategy optimize treatment oesophageal adenocarcinoma gastro-oesophageal junctional tumor curative intent . Surgery combination peri-operative chemotherapy , use combination epirubicin , cisplatin 5-FU , defined recent MAGIC trial , result 13 % increase 5-yr survival . To improve outcome patient disease hypothesize addition pre-operative combine cetuximab-radiotherapy ( cetux-RT ) treatment could improve outcome patient category well local control .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically proven resectable adenocarcinoma low oesophagus gastricoesophageal junction Tumour stage : T23 N01 M0 , assess endoscopic ultrasound CTscan thorax abdomen ultrasound neck region . For patient treat study gastrooesophageal junctional tumor stag oesophageal tumor respect lymphnode metastasis . Age &gt; 18y write informed consent least 4 day deliberation time moment patient information give explain . Weight loss &lt; 10 % 0.5 yr WHO performance status 01 No prior radiotherapy chemotherapy adenocarcinoma oesophagus Previous malignancy basal cell carcinoma skin local resection cervical carcinoma situ . Inadequate organ function define : Inadequate haematology ( Hb &lt; 5,5 mmol/L ( red blood cell transfusion allow increase Hb discretion investigator ) neutrophils &lt; 1,5 109/L platelet &lt; 100*109/L ) , Liver enzyme elevation ( bili &gt; 1,5*ULN ASAT &gt; 2,5*ULN ALAT &gt; 2,5*ULN ) Impaired renal function ( creatinine clearance cockcroft &lt; 60 cc/min ) Proteinuria &gt; 1,0gr/24hr Tumour stage : M1a and/or tumour length &gt; 8 cm and/or &gt; 5 cm radially Major surgery within 4 week prior start study treatment Bleeding disorder Known allergy one study drug use Use substance know interfere chemotherapy clearance Previous radiotherapy chest Significant concomitant disease prevent safe administration study drug likely interfere study assessment Uncontrolled angina pectoris ; cardiac failure clinically significant arrhythmia Continuous use immunosuppressive agent Concurrent use antiviral agent sorivudine chemically related analogue , brivudine Prior exposure antiEGFR target agent . Hearing loss &gt; 25 dB normal Neurotoxicity &gt; CTC grade 1 Pregnancy breast feeding Patients ( M/F ) reproductive potential implementing adequate contraceptive measure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>